Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-Small Cell Lung Cancer and Preexisting Interstitial Lung Diseases

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

(2021) Ahmet Sezer et al.   LANCET

Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease

(2021) Yuri Tasaka et al.   LUNG CANCER

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence

(2020) Seonggyu Byeon et al.   Cancer Medicine

Immune-related adverse events of checkpoint inhibitors

(2020) Manuel Ramos-Casals et al.   Nature Reviews Disease Primers

Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease

(2020) Tetsuo Fujita et al.   INTERNAL MEDICINE

A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis

(2020) Satoshi Ikeda et al.   Journal of Thoracic Oncology

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

(2020) Roy S. Herbst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease

(2019) Ryota Shibaki et al.   MEDICAL ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

(2019) Ken Kato et al.   LANCET ONCOLOGY

Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial

(2019) Daichi Fujimoto et al.   LUNG CANCER

P1.01-62 Association of Baseline Pulmonary Fibrosis with the Outcome of PD-1 Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer

(2019) S. Mao et al.   Journal of Thoracic Oncology

Prescribed Dose of Opioids and Overdose: A Systematic Review and Meta-Analysis of Unintentional Prescription Opioid Overdose

(2018) Adeleke D. Adewumi et al.   CNS DRUGS

Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease

(2018) Osamu Kanai et al.   Thoracic Cancer

Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities

(2018) Karthik Suresh et al.   CHEST

Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors

(2018) Karthik Suresh et al.   Journal of Thoracic Oncology

Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

(2018) Jun Yeun Cho et al.   LUNG CANCER

Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis

(2018) Teppei Yamaguchi et al.   LUNG CANCER

A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia

(2017) Daichi Fujimoto et al.   LUNG CANCER

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors

(2016) Claire F. Friedman et al.   JAMA Oncology

Characteristics of and Risk Factors for Interstitial Lung Disease Induced by Chemotherapy for Lung Cancer

(2015) Takumi Sakurada et al.   ANNALS OF PHARMACOTHERAPY

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer

(2011) Hirotsugu Kenmotsu et al.   Journal of Thoracic Oncology